Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Spot tests

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    57 result(s) found for: Spot tests. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2011-006151-10 Sponsor Protocol Number: FAME1.0 Start Date*: 2012-02-15
    Sponsor Name:Sønderjylland Hospital, department of neurology
    Full Title: FAME - Fampyra outcome measures study: a study of responsiveness of different outcome measures to Fampyra treatment.
    Medical condition: Multiple Sclerosis
    Disease:
    Population Age: Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001083-16 Sponsor Protocol Number: DCR-PHXC-203 Start Date*: 2021-10-04
    Sponsor Name:Dicerna Pharmaceuticals Inc
    Full Title: A Phase 2 Open-Label Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Nedosiran in Pediatric Patients from Birth to 11 Years of Age with Primary Hyperoxaluria and Relativ...
    Medical condition: Primary Hyperoxaluria
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10020703 Hyperoxaluria PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing) PL (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-002592-34 Sponsor Protocol Number: RID-TB:Dx Start Date*: 2020-08-28
    Sponsor Name:University College London
    Full Title: Research to Improve the Detection and Treatment of Latent Tuberculosis Infection: Diagnostics (RID-TB:Dx) A randomised controlled trial to evaluate the effectiveness of using the RD-1 based C Tb s...
    Medical condition: Latent Tuberculosis infection (LTBI)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10065048 Latent tuberculosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-000893-32 Sponsor Protocol Number: 008171BLT Start Date*: 2014-02-17
    Sponsor Name:Queen Mary University of London
    Full Title: Squamous cell carcinoma prevention in organ transplant recipients using topical treatments: a feasibility study (SPOT)
    Medical condition: Actinic keratosis (and cutaneous squamous cell carcinoma)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10000614 Actinic keratosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-000331-16 Sponsor Protocol Number: C-935788-050 Start Date*: 2014-07-28
    Sponsor Name:Rigel Pharmaceuticals Inc
    Full Title: A Phase 2, Multi-Center, Randomised, Double-Blind, Ascending-Dose, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of IgA Nephropathy
    Medical condition: IgA nephropathy (IgAN)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001684-21 Sponsor Protocol Number: NV1205-009 Start Date*: 2018-04-20
    Sponsor Name:Neurov Acquisition LLC
    Full Title: Phase I/II, Open-Label, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of NV1205 in Pediatric Male Subjects with Childhood Cerebral Adrenoleukodystrophy (CCALD)
    Medical condition: Childhood Cerebral Adrenoleukodystrophy (CCALD)
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: GB (Prematurely Ended) FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2014-000706-34 Sponsor Protocol Number: A3921237 Start Date*: 2014-10-06
    Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, NY 10017
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO ASSESS THE IMMUNE RESPONSE FOLLOWING ADMINISTRATION OF ZOSTER VACCINE TO SUBJECTS WITH RHEUMATOID ARTHRITIS RECEIVING TOFACITINIB (C...
    Medical condition: RHEUMATOID ARTHRITIS
    Disease: Version SOC Term Classification Code Term Level
    17.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-003826-10 Sponsor Protocol Number: EAGLE Start Date*: 2014-01-24
    Sponsor Name:IRCCS- Mario Negri Institute
    Full Title: EVALUATING THE MORPHOFUNCTIONAL EFFECTS OF ECULIZUMAB THERAPY IN PRIMARY MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS: A PILOT, SINGLE ARM STUDY IN TEN PATIENTS WITH PERSISTENT HEAVY PROTEINURIA
    Medical condition: Membranoproliferative glomerulonephritis
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-000285-38 Sponsor Protocol Number: APHP190020 Start Date*: 2019-08-21
    Sponsor Name:London School of Hygiene and Tropical Medicine
    Full Title: Pharmacokinetics of Tranexamic Acid after oral, intramuscular or intravenous administration: a prospective, randomised, cross-over trial in healthy volunteers.
    Medical condition: healthy volunteers
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-003453-34 Sponsor Protocol Number: 201755 Start Date*: 2015-06-18
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Phase IIb, Double-Blind, Placebo-Controlled, Dose-Adaptive, Study of the Efficacy and Safety of GSK3196165 in Combination with Methotrexate Therapy, in Subjects with Active Moderate-Severe Rheuma...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) DE (Completed) HU (Completed) CZ (Completed) ES (Completed) GB (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-001793-36 Sponsor Protocol Number: GTX-102-001 Start Date*: 2023-04-26
    Sponsor Name:Ultragenyx Pharmaceutical Inc.
    Full Title: A Phase 1/2 Open-label, Multiple-dose, Dose-escalating Clinical Trial of the Safety and Tolerability of GTX-102 in Pediatric Patients With Angelman Syndrome (AS)
    Medical condition: Angelman Syndrome
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-003206-69 Sponsor Protocol Number: ASST-FARM-CAR_STEROHF-2022 Start Date*: 2023-01-30
    Sponsor Name:AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA
    Full Title: A multicenter, randomized, open-label, controlled study to evaluate the efficacy and safety of corticoSTEROids added to standard therapy in patients with Acute Heart Failure (STERO-AHF)
    Medical condition: patients with Acute Heart Failure
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007556 Cardiac failure acute PT
    20.0 10007541 - Cardiac disorders 10007556 Cardiac failure acute PT
    20.0 10007541 - Cardiac disorders 10066332 Acute cardiac insufficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-001318-11 Sponsor Protocol Number: PB-102-F30 Start Date*: 2017-03-24
    Sponsor Name:Protalix Ltd.
    Full Title: An Open Label Study of the Safety and Efficacy of PRX 102 in Patients with Fabry Disease Currently Treated With REPLAGAL® (Agalsidase alfa)
    Medical condition: Fabry disease (α-galactosidase A deficiency)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10010331 - Congenital, familial and genetic disorders 10016016 Fabry's disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) CZ (Completed) DE (Completed) SI (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2017-001528-23 Sponsor Protocol Number: PB-102-F50 Start Date*: 2017-10-18
    Sponsor Name:Protalix Ltd.
    Full Title: A Phase 3, Open Label, Switch Over Study to Assess the Safety, Efficacy and Pharmacokinetics of pegunigalsidase alfa (PRX-102) 2 mg/kg Administered by Intravenous Infusion Every 4 Weeks for 52 week...
    Medical condition: Fabry disease (α-galactosidase A deficiency)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10016016 Fabry's disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) ES (Completed) CZ (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-015884-15 Sponsor Protocol Number: IMPAACT-P1066 Start Date*: 2011-06-30
    Sponsor Name:The National Institute of Allergy and Infectious Diseases (NIAID) and The Eunice Kennedy Shriver NICHD
    Full Title: A Phase I/II, Multicenter, Open-Label, Non comparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmac...
    Medical condition: HIV
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-001818-14 Sponsor Protocol Number: RELATE-TRD Start Date*: 2013-12-20
    Sponsor Name:University Medical Center Groningen
    Full Title: RELATE and PREDICT TRD A pharmacological and neuroimaging study investigating neurobiological effects of Selective Serotonin Reuptake Inhibitors and Norepinephrine Reuptake inhibitors on dopaminer...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    16.0 10037175 - Psychiatric disorders 10012378 Depression PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-000378-38 Sponsor Protocol Number: PB-102-F20 Start Date*: 2016-09-07
    Sponsor Name:Protalix Ltd.
    Full Title: A Randomized, Double blind, Active Control Study of the Safety and Efficacy of PRX-102 compared to Agalsidase Beta on Renal Function in Patients with Fabry Disease Previously Treated With Agalsidas...
    Medical condition: Fabry disease (α-galactosidase A deficiency)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10016016 Fabry's disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) HU (Completed) ES (Completed) CZ (Completed) NO (Completed) BE (Completed) NL (Completed) SI (Completed) IT (Completed) FI (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-000841-28 Sponsor Protocol Number: DC2017DECREASE01 Start Date*: 2017-08-14
    Sponsor Name:VU University Medical Center
    Full Title: Combined effects of SGLT2 inhibition and GLP-1 receptor agonism on food intake, body weight and central satiety and reward circuits in obese T2DM patients
    Medical condition: Type 2 diabetes mellitus Obesity
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-003089-96 Sponsor Protocol Number: 204851 Start Date*: 2016-01-06
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A multi-centre Phase IIa double-blind, placebo-controlled study to investigate the efficacy and safety of GSK3196165 in subjects with inflammatory hand osteoarthritis.
    Medical condition: Inflammatory Hand Osteoarthritis
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004859 10019115 Hand osteoarthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) NL (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-000850-36 Sponsor Protocol Number: 201600136 Start Date*: 2017-05-01
    Sponsor Name:Archivel Farma S.L.
    Full Title: Double-Blind, Randomized, Placebo-Controlled Phase IIa Clinical Trial to Investigate the Safety and Immunogenicity of RUTI® Therapeutic Vaccination in Patients with Multi-Drug Resistant Tuberculos...
    Medical condition: The medical condition to be investigated is culture-confirmed Multidrug-resistant tuberculosis, i.e. tuberculosis resistant to the two first-line drugs Rifampicin and Isoniazid
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 15 07:45:53 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA